Last reviewed · How we verify
Midodrine Oral Tablet
Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels.
Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels. Used for Orthostatic hypotension, Symptomatic hypotension.
At a glance
| Generic name | Midodrine Oral Tablet |
|---|---|
| Also known as | ProAmatine®, Midodrine pill, ProAmatine, Midodrine hydrochloride |
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Drug class | Alpha-1 adrenergic agonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Midodrine is a prodrug that is metabolized to desglymidodrine, its active metabolite, which selectively stimulates alpha-1 adrenergic receptors on arterioles and venules. This peripheral vasoconstriction increases both systolic and diastolic blood pressure, making it useful for treating conditions characterized by abnormally low blood pressure. The drug does not cross the blood-brain barrier significantly, limiting central nervous system effects.
Approved indications
- Orthostatic hypotension
- Symptomatic hypotension
Common side effects
- Hypertension
- Piloerection (goosebumps)
- Pruritus
- Headache
- Urinary retention
Key clinical trials
- Midodrine Effect on the Mortality Rates in Septic Shock Patients (PHASE2)
- Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension (PHASE2, PHASE3)
- Treatment Strategy of Vasovagal Syncope (NA)
- Preoperative Oral Midodrine Versus Intraoperative Intravenous Norepinephrine in Preventing Post-spinal Anesthesia Hypotension in Cesarean Section: A Prospective Double-blind Randomized Clinical Trial (NA)
- To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. (NA)
- Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population (NA)
- Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury (NA)
- Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midodrine Oral Tablet CI brief — competitive landscape report
- Midodrine Oral Tablet updates RSS · CI watch RSS
- Institute of Liver and Biliary Sciences, India portfolio CI